Skip to main content
. 2020 Nov 10;6(5):1423–1435. doi: 10.1016/j.bioactmat.2020.10.020

Fig. 4.

Fig. 4

In vivo MRI and distribution. In vivo T1 weighted images (A) and relative T1 MRI signal intensity (C) of tumors following the administration of SAPEG-MPDA@SPIO/DOX/Fe3+ and PEG-MPDA@SPIO/DOX/Fe3+ NPs at different time points. In vivo T2 weighted images (B) and relative T2 MRI signal intensity (D) of tumors following the administration of SAPEG-MPDA@SPIO/DOX/Fe3+ and PEG-MPDA@SPIO/DOX/Fe3+ NPs at different time points. (E) The fluorescence images of HepG2-bearing mice treated with SAPEG-MPDA@SPIO/ICG/Fe3+ and PEG-MPDA@SPIO/ICG/Fe3+ at different time point. The fluorescence images (F) and fluorescence intensity (G) of harvested tissue at 24 h post-injection. (*P < 0.05, n = 3).